Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) through suppression of NF-κB signaling and nuclear retention of tumor suppressor proteins. We tested selinexor i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Bahlis, Nizar J., Sutherland, Heather, White, Darrell, Sebag, Michael, Lentzsch, Suzanne, Kotb, Rami, Venner, Christopher P., Gasparetto, Cristina, Del Col, Aldo, Neri, Paola, Reece, Donna, Kauffman, Michael, Shacham, Sharon, Unger, T. J., Jeha, Jacqueline, Saint-Martin, Jean-Richard, Shah, Jatin, Chen, Christine
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6302280/
https://ncbi.nlm.nih.gov/pubmed/30352784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-06-858852
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados